Search

Displaying results 5231 - 5240 of 9889 in total
  1. Drug

    Sipagladenant

    go.drugbank.com/drugs/DB17080
    Investigational

    KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin.[L43822]

  2. Drug

    Tinlorafenib

    go.drugbank.com/drugs/DB17082
    Investigational

    Tinlorafenib (PF-07284890) is a potent, selective, highly brain-penetrant, small-molecule inhibitor of BRAF V600 mutations.[A253992]

  3. Drug

    Gadopiclenol

    go.drugbank.com/drugs/DB17084
    ApprovedInvestigational

    Gadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure. … [A254002] Gadopiclenol has high kinetic stability and a high r1 relaxivity, allowing it to be used at lower doses than classic extracellular GBCAs.

  4. Drug

    KDT-3594

    go.drugbank.com/drugs/DB17085
    Investigational

    KDT-3594 is a non-ergot dopamine receptor agonist developed by Kissei Pharmaceutical.

  5. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    [A254232] UCB7362 is estimated to achieve a significant reduction in asexual blood-stage parasites.

  6. Drug

    Briquilimab

    go.drugbank.com/drugs/DB18136
    Investigational

    Briquilimab is a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit).

  7. Drug

    ATX-01

    go.drugbank.com/drugs/DB18141
    Investigational

    ATX-01 is an antimiR, a chemically modified antisense oligonucleotide, designed to target microRNA 23b (miR-23b).

  8. Drug

    MTL-CEBPA

    go.drugbank.com/drugs/DB18143
    Investigational

    MTL-CEBPA is a SMARTICLES liposomal formulation of MTL-501, a small activating RNA (saRNA) oligonucleotide.

  9. Drug

    BRG01

    go.drugbank.com/drugs/DB18173
    Investigational

    BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.[L48111]

  10. Drug

    Etavopivat

    go.drugbank.com/drugs/DB18176
    Investigational

    Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.